Infinitam (etanercept biosimilar) / Probiomed - LARVOL DELTA

Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort (ACR Convergence 2024) - "Patients who were switched from an originator biological to its biosimilar were followed up every 3 months; biological therapies included were: Adalimumab (ADA), Rituximab (RTX) and Etanercept (ETN), with their biosimilars Amgevita, Maball and Infinitam, respectively. Switching of originator biological therapies to its biosimilar in our cohort of patients might not have an impact on efficacy or the incidence of infections; however, one of the most common AEs was associated with the mechanics of the autoinjector device. Although this may seem a minor issue, it led to patients missing a dose, thus having an impact on treatment compliance and thus the activity of the disease."

Clinical • Ankylosing Spondylitis • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Systemic Lupus Erythematosus

Not the same, but is it the same? Cycling of biologic agents in rheumatoid arthritis. Experience in the Instituto Mexicano del Seguro Social. (PubMed, Reumatol Clin (Engl Ed)) - "The persistence of treatment after switching from an innovative drug to a biocomparable or a non- biocomparable in RA patients did not show statistically significative differences in our cohorts, but we did find a higher number of adverse events when comparing those who were changed with those who continued on an innovative drug. Twenty patients in the switch groups had to receive a new drug with a different biological target due to lack of efficacy of the switched drug."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Not the same, but ¿is it the same? Cycling of biologic agents in rheumatoid arthritis. Experience in the Instituto Mexicano del Seguro Social. (PubMed, Reumatol Clin) - "The persistence of treatment after switching from an innovative drug to a biocomparable or a non-biocomparable in RA patients did not show statistically significative differences in our cohorts, but we did find a higher number of adverse events when comparing those who were changed with those who continued on an innovative drug. Twenty patients in the switch groups had to receive a new drug with a different biological target due to lack of efficacy of the switched drug."

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

"Este pedazo de plástico que venía pegado a caja de Dolex Forte, es supremamente contaminante e infinitamente innecesario. A mi si me molesta cuando se abusa del plástico en los empaques. @MinAmbienteCo @Secretariadesa @GSKUS @GSK @GSK_Oralhealth @AulasGSK @NCGSKFound @GSK_bio" (@GigiDeGal)

"Agradezco infinitamente a mi @RDBSeleccion por el gran desempeño mostrado en el #WCLC19 cada Dominicano está orgulloso por el gran corazón mostrado en cada jugada." (@ManuelG59367134)

"Los sé, y sabes que te estoy infinitamente agradecida!!" (@AnaAngiolina)